MBX

MBX BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$51.74

Analysis reference price unavailable

Analysis 2025-11-29 · RankAlpha Sentiment AI

Most likely

Base case

50%

Probability

Target price

$37.94

Analysis reference price unavailable

Analysis 2025-11-29 · RankAlpha Sentiment AI

B-

Bear case

25%

Probability

Target price

$24.14

Analysis reference price unavailable

Analysis 2025-11-29 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2025-11-29

AI commentary

Mixed-to-cautious. Recent price action shows modest stability, but investors remain highly sensitive to clinical readouts and financing news [#RankAlpha-2025-11-28]. Near-term sentiment is event-driven (readouts, filings, partnership announcements); longer-term views hinge on binary clinical outcomes [#PR].

RankAlpha Sentiment AI - 2025-11-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventClinical/regulatory readout or milestoneHigh impact

Potential clinical data release or regulatory update that could materially re-rate the stock on positive efficacy/safety news [#PR].

-catalystQuarterly financial/operational missHigh impact

An earnings or operational miss (10-Q/press release) could trigger a pronounced downmove given small‑cap liquidity [#10Q].

-catalystPartnership / licensing announcementHigh impact

Strategic collaboration or licensing deal could provide validation and non-dilutive funding, supporting upside [#IR].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-29 • Updated nightlySource: Internal modelMethodology